Extended Research →
Verdict, decision matrix, deep dives, sourcing notes & full sources
Modafinil
Extensively StudiedBest evidence-base eugeroic on the planet for sustained cognitive output without amphetamine downsides — 100mg AM, 5-6×/week is the sweet… | Pharmaceutical · Oral
Aliases (10)
Provigil · Modalert · Modvigil · ModaXL · Modafil · Modiodal · Alertec · Vigil · Provake · 2-(diphenylmethyl)sulfinylacetamide
TYPICAL DOSE
100mg
ROUTE
Oral (tablet)
CYCLE
5-6 days on, 1-2 days off
STORAGE
Room temp; original container
✎
Suggest an edit
Did you know?
You can suggest edits to improve this compound's information.
Submitted via email — no account required.
▸Brand options8 known
ProvigilModalertModvigilModaXLModafilModiodalAlertecVigil
StatusSchedule IV (US DEA) | Class B Rx (Canada) | POM (UK) | Rx-required most jurisdictions
▸ Overview TL;DR
Best evidence-base eugeroic on the planet for sustained cognitive output without amphetamine downsides — 100mg AM, 5-6×/week is the sweet spot for Dylan. Watch for rash in the first 8 weeks (SJS, ~1/5000) and stop immediately if any appears. Sourcing: Indian pharmacy ($0.50-1.50/pill) or US telehealth via narcolepsy/SWSD diagnosis.
▸ Mechanism of action
Modafinil is an atypical wakefulness promoter with a multi-system mechanism that's still not fully mapped after 30 years of research. It's not a classical stimulant — it doesn't force monoamine release like amphetamine.
Primary action — DAT inhibition (the "stim-like" component):
- Modafinil binds the dopamine transporter (DAT) competitively. PET imaging (Volkow et al. 2009; Andersen et al. 2017) shows ~50-57% striatal DAT occupancy at clinical 200-300mg doses — comparable in magnitude to therapeutic methylphenidate, but with vastly different subjective and abuse profiles because the binding kinetics and Vmax effects differ.
- Result: increased extracellular dopamine in caudate, putamen, and (especially) nucleus accumbens. This is the only "classical stimulant-like" piece.
Secondary action — orexin/histamine cascade (the "wake" component):
- Modafinil indirectly potentiates lateral hypothalamus orexin neurons → orexin then drives histaminergic neurons in the tuberomammillary nucleus → cortical histamine rises → wakefulness without sympathetic overdrive.
- Histamine ablation knockouts blunt modafinil's wake effect (Parmentier et al. 2019), confirming this pathway.
- Modafinil also works in orexin-receptor knockouts (just less effectively), so the system is redundant.
Tertiary actions:
- Increases glutamate (especially in hypothalamus, thalamus, hippocampus) and decreases GABA tone.
- Indirectly raises norepinephrine and serotonin in PFC and hypothalamus.
- Possible D1R contribution to motivational effects (Sanchez et al. 2019).
- Weak alpha-1 adrenergic activation contributes to vigilance.
The "atypical" puzzle: No single receptor explains it. Modafinil hits maybe 8-10 systems weakly and they sum to: alert, focused, motivated, no euphoria, no peripheral overstim, low abuse, low tolerance.
▸ Pharmacokinetics Approximate
t½: 12-15 hours (oral)
Approximate decay curve drawn from the half-life mention(s) in the source notes. Real PK data not yet ingested per compound.
▸Quality indicators4 checks
✓
FDA-approved manufacturer
NDC code on the bottle matches FDA registration. Generic OK; backyard not OK.
✓
Brand vs generic listed
Pharmacy fills should disclose substitution. AB-rated generics are bioequivalent.
✓
Tamper-evident packaging
Pharmacy seal intact, lot number + expiry visible on the bottle and the box.
!
Schedule labeling correct
C-II / C-IV warnings on label match the medication; report any mismatch to the pharmacist.
▸ What to expect Generic
- 1Day 1PK-driven acute peak per administration. Verify dose tolerated.
- 2Week 1Steady-state reached for most daily-dosed pharma.
- 3Week 2-4Therapeutic effect established; titration window if needed.
- 4Long-termPeriodic monitoring per drug class (labs, BP, ECG as applicable).
▸ Side effects + safety Tabbed view
Common (>10% users)
- Headache — ~30% of users, especially first 1-3 doses. Usually fades within a week. Mitigations: hydration, electrolytes, magnesium (already in V4), L-theanine 100-200mg co-administered, dose reduction to 50mg if persistent.
- Insomnia / shifted sleep onset — only if dosed too late or at higher doses. 100mg AM <11 AM rarely causes this.
Less common (1-10%)
- Nausea (~11% in trials)
- Anxiety (5-10%, ~1% lead to discontinuation)
- Nervousness, jitteriness
- Dizziness
- Dry mouth, increased thirst
- Diarrhea
- Back pain
- Palpitations / mild HR elevation
- Reduced appetite (more pronounced at 200mg+)
- Rhinitis-like symptoms
- Urinary frequency
Rare-serious (<1% but worth knowing)
- Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN) / DRESS — life-threatening dermatologic reactions. Estimated ~1/5000 to 1/20000. Almost all reported cases occurred within 1-5 weeks of starting; nearly all within 6 weeks. A handful of late cases reported up to 3 months. Rule: stop immediately if any rash develops in the first 8 weeks, see a doctor same-day if rash + fever, mucosal involvement, or skin peeling. The 2007 FDA pediatric SJS case is what killed the modafinil-for-ADHD approval pathway.
- Hypersensitivity / multi-organ reaction — same watch period as SJS.
- Cardiovascular events — premature ventricular contractions, mild BP elevation. Contraindicated in uncontrolled HTN, recent MI, LVH, mitral valve prolapse with prior reactions to stimulants.
- Psychiatric — psychosis, mania, hallucinations, suicidal ideation. Very rare in people without pre-existing psychiatric history. Higher risk in bipolar (can trigger manic switch).
- Fetal harm — modafinil is teratogenic; congenital heart defects, hypospadias, growth restriction documented. Contraindicated in pregnancy. Reduces hormonal contraceptive efficacy (see Drug Interactions).
- Angioedema, anaphylaxis — rare, immediate-discontinue if seen.
Specific watch periods
- Weeks 1-8: SJS rash watch — any new rash, especially with fever or mucosal symptoms (mouth sores, eye redness), is a stop-the-drug-now event. Photograph and seek care.
- Weeks 1-2: headache adjustment — if headache persists beyond 2 weeks, drop dose to 50mg or stop.
- First week: anxiety calibration — if anxiety rises sharply or resembles a panic attack, lower dose or add L-theanine 200mg with each dose. If still bad after a week, stop.
- First 2-3 cycles: sleep architecture watch — even with morning-only dosing, some users have reduced REM/deep sleep on dose days. Track with Oura/ring or subjective rest. Acceptable trade-off only if cognition gain > sleep cost.
▸Interactions12 compounds
- l-theanine (200mg co-administered):SynergisticSingle best stack. Smooths anxiety, reduces tension headache, doesn't blunt cognition. Already in Dylan's V4.
- caffeineSynergistic(post-modafinil onboarding only): Once Dylan has caffeine baseline established, ~100-200mg caffeine + 100mg modafinil layers nicely. Not on day 1.
- bromantaneSynergistic(planned V5 add at week 4-6): Different mechanism (DAT/SERT modulation + tyrosine hydroxylase upregulation), no overlap, plausibly synergistic for sustained …
- citicolineSynergistic(already V4, 500mg): Cholinergic support helps sustain modafinil's pro-cognitive effect on long workdays. Dylan covered.
- rhodiolaSynergistic(already V4, 250mg): Anxiolytic adaptogen, smooths the adrenergic edge.
- selegilineSynergistic(planned V5 optional, 1-2.5mg): MAO-B selective inhibition preserves dopamine; pairs well with modafinil's DAT effect. Caution: above 10mg/day selegiline los…
- alpha-gpcSynergistic(Dylan's PRN): Acute cholinergic boost for high-load days. Don't stack daily — modafinil + Alpha-GPC + already-V4 citicoline is too much choline.
- MAO inhibitors (non-selective)AvoidTranylcypromine, phenelzine, etc. — risk of hypertensive crisis. Selegiline at low MAO-B-selective doses (1-2.5mg) is fine.
- Other strong DAT/NET stimulants dailyAvoid(amphetamines, high-dose methylphenidate): Cumulative cardiovascular load, no additional cognitive benefit.
- Yohimbine, high-dose synephrineAvoidStacked alpha-1/alpha-2 effects = anxiety + BP spike.
- Other CYP3A4 inducers dailyAvoid(rifampin, St. John's Wort, carbamazepine): Compound the contraceptive/opioid efficacy reduction.
- Hormonal contraceptivesAvoid(relevant for partners, not Dylan): See Drug Interactions.
▸References23 sources
Battleday & Brem 2015 — Modafinil for cognitive neuroenhancement systematic review
2015landmark review concluding consistent benefit on complex tasks in non-sleep-deprived healthy adults.
pubmed.ncbi.nlm.nih.govView →
Roberts et al. 2020 — Pharmaceutical cognitive enhancement meta-analysis
2020pooled effect sizes for modafinil (g ~0.10-0.28), methylphenidate, d-amphetamine.
pubmed.ncbi.nlm.nih.govView →
Volkow et al. 2009 JAMA — DAT occupancy in human brain via PET
2009established that modafinil hits DA system at therapeutic doses.
pmc.ncbi.nlm.nih.govView →
Andersen et al. 2014 — DAT occupancy 51-57% at 200-300mg
2014replicated and quantified the DAT story.
academic.oup.comView →
Modafinil — StatPearls 2024 NCBI Bookshelf
2024current clinical reference; SJS, contraceptive interactions, dosing.
ncbi.nlm.nih.govView →
Modafinil — Wikipedia 2026 (PK detail, regulatory)
2026pharmacokinetics, brand names, recent regulatory updates.
en.wikipedia.orgView →
Pharmacokinetics of armodafinil and modafinil in OSA patients
R/S enantiomer PK comparison.
pubmed.ncbi.nlm.nih.govView →
Cesta et al. 2023 — Pitolisant-bridged drug holidays for modafinil tolerance
2023first formal data on tolerance management.
sciencedirect.comView →
Long-term efficacy of modafinil in narcolepsy (40-week)
no tolerance development across long-term clinical use.
sciencedirect.comView →
HSA Singapore SJS warning — armodafinil/modafinil cluster
9 hospitalized cases, watch period guidance.
hsa.gov.sgView →
FDA Provigil label 2015
2015official PK, contraceptive interaction data, side-effect frequencies.
accessdata.fda.govView →
Drug interaction evaluation — modafinil cocktail trial protocol
CYP3A4 induction quantified.
pmc.ncbi.nlm.nih.govView →
Loureiro et al. 2022 — Modafinil in preadolescent rat: PFC D2 + GABA effects
2022animal data informing brain-development concern.
pmc.ncbi.nlm.nih.govView →
Performance enhancement at the cost of brain plasticity — Frontiers 2014
2014review of nootropic risks in developing brain.
frontiersin.orgView →
Jacobs & Bell 2004 — modafinil exercise time-to-exhaustion at 85% VO2max
2004original endurance study.
pubmed.ncbi.nlm.nih.govView →
Rattray 2019 — modafinil cognitive + physical post-mental-exertion
2019partial replication, mixed endurance signal.
pubmed.ncbi.nlm.nih.govView →
Mereu et al. 2017 — modafinil reframed as atypical CNS stimulant
2017modern mechanistic synthesis.
pmc.ncbi.nlm.nih.govView →
Modafinil mechanisms — Minzenberg & Carter 2008
2008comprehensive neurochemistry review (still widely cited).
nature.comView →
PsychSceneHub — modafinil/armodafinil mechanism clinical synthesis
accessible clinical pharmacology summary.
psychscenehub.comView →
Sleep deprivation interindividual variability — Frontiers Pharmacology 2025
2025recent work on responder/non-responder phenotypes.
pmc.ncbi.nlm.nih.govView →
WADA Prohibited List 2026
2026modafinil banned S6 stimulant (in-competition), since 2004.
wada-ama.orgView →
ModafinilXL vendor profile (Trustpilot + buymoda comparison)
2025sourcing reference 2025-2026.
buymoda.netView →
BuyModa shutdown announcement May 2025
2025domain compromise warning, ModaMike successor.
buymodaopinion.comView →
Was this helpful?
Your feedback shapes what we research deeper.
Continue: Extended Research →
Our verdict, decision matrix, deep dives, controversies, sources
Related compounds
Cross-referenced from ModafinilArmodafinil
STRONG-CANDIDATE
Eugeroic (R-enantiomer of modafinil)
MEDIUM
Adrafinil
SKIP-PERMANENT
Eugeroic — modafinil prodrug
HIGH
THN102
SKIP-FOR-NOW
Fixed-dose combination eugeroic — modafinil + astroglial connexin 30 (Cx30) inhibitor (subtherapeutic flecainide)
HIGH
Solriamfetol
WATCH-LIST
DNRI (dopamine + norepinephrine reuptake inhibitor) — wakefulness-promoting agent; secondary TAAR1 + 5-HT1A agonism (preclinical)
MEDIUM
Pitolisant
SKIP-FOR-NOW
Histamine H3 receptor inverse agonist / antagonist — first-in-class wakefulness-promoting agent (non-stimulant, non-controlled)
MEDIUM
Caffeine
STRONG-CANDIDATE
Methylxanthine — non-selective adenosine receptor antagonist (CNS stimulant)
HIGH
L-Theanine
STRONG-CANDIDATE
Non-proteinogenic amino acid; glutamate / glutamine analog
HIGH
Bromantane
STRONG-CANDIDATE
Adamantane-derivative actoprotector / atypical psychostimulant + anxiolytic (Russian)
MEDIUM
Selegiline
STRONG-CANDIDATE
Selective irreversible MAO-B inhibitor (loses selectivity dose-dependently); catecholaminergic activity enhancer (CAE) via TAAR1
MEDIUM
More in Pharmaceutical · Oral
89 compounds in bucket3-n-Butylphthalide (NBP)
OPTIONAL-ADD
Plant-derived multi-target neuroprotectant (phthalide; originally isolated from celery seed Apium graveolens); approved Chinese pharmaceutical for acute ischemic stroke
LOW
9-Methyl-β-carboline
WATCH-LIST
β-carboline alkaloid (tricyclic pyridoindole) — multimodal dopaminergic neurorestorative + dual MAO-A/B inhibitor + neurotrophic-factor inducer
LOW
ACD-856
WATCH-LIST
Pan-Trk receptor positive allosteric modulator (Trk-PAM) — small-molecule triazinetrione
HIGH
Adderall
SKIP-FOR-NOW
Amphetamine — substituted phenethylamine releasing agent (SNDRA)
MEDIUM
Adrafinil
SKIP-PERMANENT
Eugeroic — modafinil prodrug
HIGH
AF710B
SKIP-FOR-NOW
Dual-mechanism small molecule — M1 muscarinic positive allosteric modulator (PAM) + sigma-1 receptor agonist
HIGH